Agios Pharmaceuticals, Inc. (0HB0.L)
USD 41.74
(-0.05%)
USD 41.74
(-0.05%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -391.48 Million USD | -0.63% |
| 2022 | -389.04 Million USD | -2.81% |
| 2021 | -378.41 Million USD | -12.65% |
| 2020 | -335.91 Million USD | 21.21% |
| 2019 | -426.33 Million USD | -17.62% |
| 2018 | -362.47 Million USD | -12.99% |
| 2017 | -320.79 Million USD | -59.61% |
| 2016 | -200.98 Million USD | -69.32% |
| 2015 | -118.7 Million USD | -119.27% |
| 2014 | -54.13 Million USD | -39.22% |
| 2013 | -38.88 Million USD | -69.09% |
| 2012 | -22.99 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -105.81 Million USD | -14.93% |
| 2024 Q3 | -102.81 Million USD | 2.84% |
| 2024 Q1 | -92.07 Million USD | 13.37% |
| 2023 Q1 | -90.61 Million USD | 8.63% |
| 2023 Q4 | -106.27 Million USD | -5.33% |
| 2023 FY | -391.48 Million USD | -0.63% |
| 2023 Q3 | -100.89 Million USD | -7.68% |
| 2023 Q2 | -93.7 Million USD | -3.41% |
| 2022 Q3 | -91.09 Million USD | 6.71% |
| 2022 FY | -389.04 Million USD | -2.81% |
| 2022 Q4 | -99.17 Million USD | -8.87% |
| 2022 Q2 | -97.64 Million USD | 3.47% |
| 2022 Q1 | -101.14 Million USD | 3.51% |
| 2021 Q1 | -91.21 Million USD | -6.9% |
| 2021 Q2 | -91.22 Million USD | -0.01% |
| 2021 Q3 | -91.15 Million USD | 0.08% |
| 2021 Q4 | -104.82 Million USD | -15.0% |
| 2021 FY | -378.41 Million USD | -12.65% |
| 2020 Q4 | -85.33 Million USD | -6.28% |
| 2020 Q1 | -87.03 Million USD | 17.84% |
| 2020 Q2 | -83.26 Million USD | 4.33% |
| 2020 FY | -335.91 Million USD | 21.21% |
| 2020 Q3 | -80.29 Million USD | 3.57% |
| 2019 FY | -426.33 Million USD | -17.62% |
| 2019 Q4 | -105.92 Million USD | 2.87% |
| 2019 Q2 | -113.86 Million USD | -16.8% |
| 2019 Q3 | -109.06 Million USD | 4.22% |
| 2019 Q1 | -97.48 Million USD | -1.17% |
| 2018 Q2 | -72.94 Million USD | 22.4% |
| 2018 FY | -362.47 Million USD | -12.99% |
| 2018 Q4 | -96.35 Million USD | 2.83% |
| 2018 Q3 | -99.16 Million USD | -35.93% |
| 2018 Q1 | -94.01 Million USD | -4.31% |
| 2017 Q3 | -79.01 Million USD | 6.6% |
| 2017 Q4 | -90.13 Million USD | -14.06% |
| 2017 FY | -320.79 Million USD | -59.61% |
| 2017 Q1 | -67.04 Million USD | -16.79% |
| 2017 Q2 | -84.6 Million USD | -26.18% |
| 2016 Q1 | -23.59 Million USD | 42.31% |
| 2016 Q2 | -56.47 Million USD | -139.34% |
| 2016 Q3 | -63.51 Million USD | -12.47% |
| 2016 FY | -200.98 Million USD | -69.32% |
| 2016 Q4 | -57.4 Million USD | 9.61% |
| 2015 FY | -118.7 Million USD | -119.27% |
| 2015 Q3 | -40.47 Million USD | -25.96% |
| 2015 Q2 | -32.13 Million USD | -518.54% |
| 2015 Q1 | -5.19 Million USD | 80.56% |
| 2015 Q4 | -40.89 Million USD | -1.05% |
| 2014 Q3 | 3.2 Million USD | 117.5% |
| 2014 FY | -54.13 Million USD | -39.22% |
| 2014 Q4 | -26.72 Million USD | -933.14% |
| 2014 Q1 | -12.28 Million USD | -0.34% |
| 2014 Q2 | -18.33 Million USD | -49.22% |
| 2013 Q4 | -12.24 Million USD | -10.6% |
| 2013 Q1 | -7.04 Million USD | -8.45% |
| 2013 Q2 | -8.52 Million USD | -21.0% |
| 2013 Q3 | -11.06 Million USD | -29.83% |
| 2013 FY | -38.88 Million USD | -69.09% |
| 2012 FY | -22.99 Million USD | 0.0% |
| 2012 Q4 | -6.49 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | -131.401% |
| Dynavax Technologies Corporation | -37.02 Million USD | -957.273% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -7330.006% |
| Perrigo Company plc | 151.9 Million USD | 357.727% |
| Illumina, Inc. | -1.06 Billion USD | 63.378% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 105.708% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 14.997% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 97.219% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 119.802% |
| Heron Therapeutics, Inc. | -110.61 Million USD | -253.919% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 109.673% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -776.457% |
| Waters Corporation | 817.67 Million USD | 147.878% |
| Biogen Inc. | 1.29 Billion USD | 130.189% |
| Sangamo Therapeutics, Inc. | -274 Million USD | -42.876% |
| Evolus, Inc. | -49.23 Million USD | -695.172% |
| Adicet Bio, Inc. | -152.03 Million USD | -157.493% |
| Cara Therapeutics, Inc. | -121.49 Million USD | -222.225% |
| bluebird bio, Inc. | -244.26 Million USD | -60.273% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | -151.658% |
| FibroGen, Inc. | -281.81 Million USD | -38.916% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 128.999% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -768.479% |
| Homology Medicines, Inc. | -48.25 Million USD | -711.288% |
| Geron Corporation | -193.94 Million USD | -101.856% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | -38.739% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -432.679% |
| Myriad Genetics, Inc. | -123.7 Million USD | -216.481% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -288.276% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 24.026% |
| Zoetis Inc. | 3.06 Billion USD | 112.756% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -712.214% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 136.006% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 301.34% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 109.088% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -899.89% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | -10.674% |
| Atara Biotherapeutics, Inc. | -276 Million USD | -41.84% |
| Verastem, Inc. | -92.08 Million USD | -325.141% |
| Nektar Therapeutics | -137.42 Million USD | -184.873% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | -68.872% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -302.115% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | -46.173% |
| OPKO Health, Inc. | -157.02 Million USD | -149.321% |
| Exelixis, Inc. | 170.88 Million USD | 329.094% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 256.033% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 464.914% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -602.143% |
| uniQure N.V. | -282.87 Million USD | -38.398% |
| Imunon, Inc. | -21.03 Million USD | -1761.526% |
| Blueprint Medicines Corporation | -486.27 Million USD | 19.493% |
| Insmed Incorporated | -709.62 Million USD | 44.832% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 215.971% |
| TG Therapeutics, Inc. | 20.63 Million USD | 1997.383% |
| Incyte Corporation | 620.52 Million USD | 163.09% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 46.106% |